P-gp transporter and its role in neurodegenerative diseases.
This paper describes an overview of recent insights concerning some socially relevant neurodegenerative diseases such as Alzheimer's (AD), Parkinson's (PD), Huntington's (HD) and Creutzfeldt-Jakob's (CJD) diseases, amyotrophic lateral sclerosis (ALS) and epilepsy. For each pathological state, the direct and/or indirect involvement of P-glycoprotein (P-gp) efflux transport is underlined. On this basis, P-gp still represents an innovative target which can offer new tools for the development of more effective and preventive therapeutic strategies for neurodegenerative disorders. For each of them, therefore, a possible use of drugs affecting P-gp transport activity has been suggested.
Rapposelli
Simona
S
Dipartimento di Scienze Farmaceutiche, Facoltà di Farmacia, Università di Pisa, Via Bonanno 6, I-56126 Pisa, Italy. rappsi@farm.unipi.it
Digiacomo
Maria
M
Balsamo
Aldo
A
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism*; D000544:Alzheimer Disease / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000473:pathology; D007562:Creutzfeldt-Jakob Syndrome / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000378:metabolism*; D010300:Parkinson Disease / Q000378:metabolism
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1